5 Key Takeaways
-
1
Schistosomiasis causes chronic inflammation and can impair growth and cognitive development in preschoolers.
-
2
Praziquantel is effective for older children and adults, but a child-friendly formulation was needed for preschoolers.
-
3
The Pediatric Praziquantel Consortium was launched in 2012 to develop a suitable treatment for children aged three months to six years.
-
4
A new formulation received positive scientific opinion from the EMA in December 2023 and WHO prequalification in May 2024.
-
5
The project faced challenges in taste and formulation, requiring innovative approaches to ensure acceptability for young children.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
